Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis.

Prostate cancer remains the most frequently diagnosed malignancy in men worldwide, yet the mechanisms driving its pathogenesis extend far beyond organ-specific factors confined to prostatic tissue. Emerging evidence increasingly demonstrates that systemic inflammatory disorders and body-wide inflammatory processes function as fundamental drivers of prostate cancer initiation and progression. This comprehensive review examines the multifaceted mechanisms by which systemic inflammation contributes to prostate carcinogenesis, synthesizing evidence from diverse inflammatory disease contexts, including obesity, rheumatoid arthritis, systemic autoimmune diseases, cardiovascular disease, and chronic kidney disease. Systemic inflammatory biomarkers, including C-reactive protein, composite inflammatory indices such as the systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio, provide accessible measures of systemic inflammatory burden with significant prognostic utility in prostate cancer prediction and outcome assessment. Multiple molecular mechanisms interconnect systemic inflammation with prostate carcinogenesis - pro-inflammatory cytokines act as endocrine signals activating proliferative pathways in prostate epithelial cells; systemic inflammation promotes recruitment of pro-tumor myeloid-derived cells; oxidative stress generates DNA damage, increasing mutation frequency; inflammatory mediators facilitate angiogenesis and vascular permeability; and chronic immune activation impairs regulatory T cell differentiation while promoting immunosuppression. Recognition of systemic inflammation as a central driver of prostate cancer opens therapeutic opportunities through lifestyle modifications that reduce the systemic inflammatory burden, pharmacologic targeting of inflammatory pathways, and the integration of inflammatory biomarkers into clinical risk stratification and treatment planning algorithms. These integrated approaches may simultaneously optimize prostate cancer outcomes while addressing cardiovascular and metabolic comorbidities, sharing common inflammatory drivers.